News & Updates

Show Multimedia Only

Venous thromboembolism risk high in prostate cancer

01 Jun 2022

Men with prostate cancer have about a 50-percent increased risk of developing venous thromboembolism, a study has found.

Venous thromboembolism risk high in prostate cancer

01 Jun 2022

Parental benefits during cardiology training vary across institutions

31 May 2022

Institutions differ considerably in their parental benefits and policies among cardiovascular training programs internationally, which underscores disparities in real-world experiences, reveals a study.

Parental benefits during cardiology training vary across institutions

31 May 2022

Male patients with Takotsubo syndrome at higher risk of death

31 May 2022

Takotsubo syndrome (TTS) in male patients exhibit a distinct high-risk phenotype that needs close in-hospital monitoring and long-term follow-up, according to a study.

Male patients with Takotsubo syndrome at higher risk of death

31 May 2022

Which SGLT2 inhibitor is safest to use?

31 May 2022 by

The risk of cardiovascular events, such as heart failure (HF) and myocardial infarction (MI), are comparable across different sodium-glucose cotransporter 2 (SGLT2) inhibitors, according to a recent real-world Japan study.

Which SGLT2 inhibitor is safest to use?

31 May 2022

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

31 May 2022

New drug applications approved by US FDA as of 16-31 May 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

31 May 2022

Shift work worsens MI reperfusion injury

30 May 2022

A recent study provides further proof that disruption of circadian rhythms by shift work leads to a higher risk of reperfusion injury in myocardial infarction (MI).

Shift work worsens MI reperfusion injury

30 May 2022

Acid reflux drug fails to show benefit in pre-eclampsia treatment

29 May 2022

Omeprazole falls short of improving the maternal circulating profile of sFlt-1 (soluble Fms-like tyrosine kinase-1), PlGF (placental growth factor), and ET-1 (endothelin-1) in women with established pre-eclampsia, as shown in a study.

Acid reflux drug fails to show benefit in pre-eclampsia treatment

29 May 2022

Polypill cuts risk of cardiovascular disease but not mortality

28 May 2022

Use of a fixed-dose combination therapy or a polypill effectively lowers cardiovascular risk factors but falls short of producing significant reductions in mortality, according to a systematic review and meta-analysis.

Polypill cuts risk of cardiovascular disease but not mortality

28 May 2022

Diabetics bear no extra heart burden after intense exercise

28 May 2022

High-intensity exercise induces comparable cardiac responses in type 2 diabetes (T2D) patients vs healthy individuals, a recent study has found.

Diabetics bear no extra heart burden after intense exercise

28 May 2022

Smoking cessation benefit on ASCVD as effective as 3 meds?

27 May 2022 by

Patients with atherosclerotic cardiovascular disease (ASCVD) who quit smoking after acute coronary syndrome or revascularization have a comparable gain in event-free years as those who are on maximal pharmaceutical treatment, according to a study presented at the ESC Preventive Cardiology 2022 annual congress.

Smoking cessation benefit on ASCVD as effective as 3 meds?

27 May 2022

News & Updates

Filter by Specialty:

Specialty:

Venous thromboembolism risk high in prostate cancer

Venous thromboembolism risk high in prostate cancer

Parental benefits during cardiology training vary across institutions

Parental benefits during cardiology training vary across institutions

Male patients with Takotsubo syndrome at higher risk of death

Male patients with Takotsubo syndrome at higher risk of death

Which SGLT2 inhibitor is safest to use?

Which SGLT2 inhibitor is safest to use?

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

Shift work worsens MI reperfusion injury

Shift work worsens MI reperfusion injury

Acid reflux drug fails to show benefit in pre-eclampsia treatment

Acid reflux drug fails to show benefit in pre-eclampsia treatment

Polypill cuts risk of cardiovascular disease but not mortality

Polypill cuts risk of cardiovascular disease but not mortality

Diabetics bear no extra heart burden after intense exercise

Diabetics bear no extra heart burden after intense exercise

Smoking cessation benefit on ASCVD as effective as 3 meds?

Smoking cessation benefit on ASCVD as effective as 3 meds?